Nantahala Capital Management - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 29 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Nantahala Capital Management ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$1,690,000
-53.6%
5,113,958
+1.1%
0.05%
-52.7%
Q2 2020$3,643,000
+121.5%
5,060,1600.0%0.11%
+77.4%
Q1 2020$1,645,000
-53.1%
5,060,160
+1.2%
0.06%
-42.6%
Q4 2019$3,510,000
+5.6%
5,000,0000.0%0.11%
-12.2%
Q3 2019$3,323,0005,000,0000.12%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2020
NameSharesValueWeighting ↓
PERKINS CAPITAL MANAGEMENT INC 2,426,300$802,0000.74%
Cowen Prime Services LLC 1,411,500$466,0000.23%
GSA CAPITAL PARTNERS LLP 1,205,873$398,0000.07%
Nantahala Capital Management 5,113,958$1,690,0000.05%
HighMark Wealth Management LLC 80,000$26,0000.02%
Kalos Management, Inc. 72,858$24,0000.01%
Qube Research & Technologies Ltd 585,187$193,0000.00%
WINTON GROUP Ltd 190,146$63,0000.00%
Ironwood Financial, llc 1,571$1,0000.00%
Virtu Financial LLC 12,049$4,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders